
Supplemental Figure 2

Dose finding studies of AREG treatment and the effect of other ligands. A

Phosphorylated Akt (Ser473) levels at different time points. shControl HCM were exposed to 16 hours of hypoxia and subsequently given 20 nM AREG in normoxia for 0, 5, 10, 20, 30 and 60 minutes (1h). Total Akt is shown. **B** pAkt (Ser473) levels after 10, 20, and 40 nM concentrations of AREG treatment. Total Akt is shown.



Supplemental Figure 2

Dose finding studies of AREG treatment and the effect of other ligands. C pAkt (Ser473) levels in 1 hour vehicle or Cetuximab (C) treated HCM after 15 hours of normoxia (Nx) or hypoxia (Hx), followed with or without subsequent 20 mM amphiregulin (AREG), epidermal growth factor (EGF), epiregulin, heparin binding EGF like growth factor (HBEGF) or transforming growth factor alpha (TGF- α) treatment for 10 minutes. One representative blot from three independent experiments is shown. **D** Densitometry of phosphorylated Akt western blots, which is expressed as a ratio of phosphorylated Akt to total Akt (pAkt/tAkt) (n=3 per group). *p<0.05, **p<0.01, ***p<0.001, n.s., nonsignificant. Data are presented as the mean \pm SD.

